Efficacy of Bempedoic Acid Plus Maximally Tolerated Statin Therapy Examined
Statin therapy alone is often insufficient to achieve appropriate lowering of LDL cholesterol levels and additional therapies are needed to complement existing therapies.
Metabolic
ACC: Dietary Cholesterol Increases Cardiovascular Disease Risk
Higher consumption of dietary cholesterol is significantly associated with a higher risk for incident CVD and all-cause mortality.
High Statin Adherence Improves Outcomes in Atherosclerotic Cardiovascular Disease
Long-term adherence to statins was associated in a linear fashion with decreased 5-year major adverse clinical events.
High Rates of Abnormal Glucose, Dyslipidemia Found in Middle School Students
Researchers found high rates of dyslipidemia and abnormal HbA1c, including 2 cases of diabetes, after screening for cardiovascular risk factors in middle school students.
Genetic Variations in Homozygous vs Heterogeneous Familial Hypercholesterolemia
Researchers analyzed the genetic differences between homo- and heterozygous familial hypercholesterolemia in a pediatric population.
CAD Risk Reduced With Statin Use in Asthma-COPD Overlap Syndrome
The risk for coronary artery disease in patients with asthma-COPD overlap syndrome who used statins was lower regardless of the duration of treatment.
High Discordance Between LDL-C, Lp(a) Reduction in Response to Evolucumab
There is a high prevalence of discordance in the reduction of low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) in response to evolocumab treatment.
Adherence to Statins Low Among Patients With ASCVD
Statin adherence linked to significantly reduced risk for MACE.
Icosapent Ethyl Treatment Linked to Significant Reduction in Total CV Events
Treatment with icosapent ethyl was associated with a substantial reduction in the risk of first, subsequent, and total ischemic events when compared with placebo in statin-treated patients with established cardiovascular (CV) disease or diabetes with other CV risk factors.
Canagliflozin Reduces Heart Failure Risk in T2D With Preserved EF
Canagliflozin reduced the risk for heart failure in the context of both reduced EF and preserved EF.
Next post in ACC 2019 Meeting Highlights
